Evidence map›Paper›PMID 35962286›Full record

ArticleJournal of cancer research and clinical oncology2023

Anti-PD-1 for the treatment of advanced cutaneous squamous cell carcinoma in elderly patients: a French multicenter retrospective survey.

Quentin Samaran, Romain Samaran, Ernestine Ferreira, Naeda Haddad, Antoine Fottorino, Hervé Maillard, Brigitte Dreno, Nicolas Meyer, David Azria, Eve Maubec and 4 more

Open access · bronzeAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 1 country.

Quentin SamaranDepartment of Dermatology, Montpellier University Hospital and Montpellier University, Montpellier, France. q-samaran@chu-montpellier.fr.ORCID http://orcid.org/0000-0002-0560-5493
Romain SamaranDepartment of Dermatology, Le Mans Hospital, Le Mans, France.
Ernestine FerreiraDepartment of Geriatrics, Montpellier University Hospital and Montpellier University, Montpellier, France.
Naeda HaddadDepartment of Dermatology, Avicenne Hospital (AP-HP) and Paris 13 University, Bobigny, France.
Antoine FottorinoDepartment of Oncodermatology, La Timone Hospital (AP-HM) and Aix-Marseille University, Marseille, France.
Hervé MaillardDepartment of Dermatology, Le Mans Hospital, Le Mans, France.
Brigitte DrenoDepartment of Dermatology, Nantes University Hospital and Nantes University, Nantes, France.
Nicolas MeyerInstitut Universitaire Du Cancer de Toulouse, Toulouse University Hospital, Toulouse, France.
David AzriaFédération Universitaire d'Oncologie Radiothérapie, ICM-Institut Régional du Cancer Montpellier, Montpellier, France.
Eve MaubecDepartment of Dermatology, Avicenne Hospital (AP-HP) and Paris 13 University, Bobigny, France.
Caroline Gaudy-MarquesteDepartment of Oncodermatology, La Timone Hospital (AP-HM) and Aix-Marseille University, Marseille, France.
Nicolas MolinariIDESP, INSERM, Department of Statistics, Univ Montpellier, CHU Montpellier, Montpellier, France.
Pierre-Emmanuel StoebnerDepartment of Dermatology, Nîmes University Hospital and Montpellier University, Nîmes, France.
Olivier DereureDepartment of Dermatology, Montpellier University Hospital and Montpellier University, Montpellier, France.
Université de Montpellier · FRAix-Marseille Université · FRCentre Hospitalier du Mans · FRUniversité Sorbonne Paris Nord · FRCentre Hospitalier Universitaire de Toulouse · FRInserm · FRInstitut de Recherche en Cancérologie de Montpellier · FRNantes Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnti-PD1 agents are currently recommended as first-line treatment in advanced cutaneous squamous cell carcinoma (acSCC) by updated European guidelines. Although acSCC frequently affects elderly patients with multiple comorbidities, this subset of patients is often excluded of registration clinical trials. PURPOSE: To assess anti-PD-1 efficacy and safety in elderly acSCC patients in real-life conditions and describe this specific population with oncogeriatric evaluation tools.

methodsA multicenter retrospective study including acSCC patients at least 70 years old treated with PD-1 inhibitors was conducted in French referral centers. The primary endpoint was the overall response rate (ORR). Secondary endpoints included safety data, time to response (TTR), duration of response (DOR), overall survival (OS), and progression-free survival (PFS).

results63 patients were included. ORR was 57.1% (95% CI 44.0-69.5), median TTR and DOR were 3 and 5.5 months respectively. Median OS was not reached (95% CI 12.5 months-not reached) at data cut-off after a median follow-up of 8 months while median PFS was 8 months. (95% CI 5 months-not reached). Grade 3-5 adverse effects occurred in 47.6% of patients. 41.3% of patients experienced degradation of ECOG performance status during anti-PD-1 treatment. Nutritional state worsened in 27% of patients and 57.1% lost weight during treatment.

conclusionIn this particular subset of acSCC patients PD-1 inhibitors obtain results similar to those obtained in younger populations included in pivotal clinical trials, with acceptable safety. A specific oncogeriatric evaluation at treatment initiation and during follow-up appears important in this setting most notably to help manage toxicity.

Indexed as

Antineoplastic Agents, ImmunologicalCarcinoma, Squamous CellSkin NeoplasmsAgedHumansImmune Checkpoint InhibitorsRetrospective StudiesAntineoplastic Agents, ImmunologicalImmune Checkpoint InhibitorsAged (MeSH)Anti-PD-1Cutaneous squamous cell carcinomaImmunotherapy (MeSH)Skin neoplasms (MeSH)

Identifiers

PMID35962286
PMCPMC9374288
OpenAlexW4290851379

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.